Asset Management One Co. Ltd. decreased its position in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 4.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 154,114 shares of the medical research company’s stock after selling 6,532 shares during the quarter. Asset Management One Co. Ltd. owned 0.15% of Laboratory Corp. of America worth $23,257,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Acrospire Investment Management LLC boosted its holdings in Laboratory Corp. of America by 16.5% in the second quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock worth $109,000 after purchasing an additional 100 shares during the last quarter. Sun Life Financial INC boosted its holdings in Laboratory Corp. of America by 9,200.0% in the second quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock worth $115,000 after purchasing an additional 736 shares during the last quarter. IFP Advisors Inc boosted its holdings in Laboratory Corp. of America by 83.9% in the second quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock worth $177,000 after purchasing an additional 523 shares during the last quarter. Hourglass Capital LLC purchased a new stake in Laboratory Corp. of America in the second quarter worth approximately $200,000. Finally, Teacher Retirement System of Texas purchased a new stake in Laboratory Corp. of America in the third quarter worth approximately $210,000. Hedge funds and other institutional investors own 91.46% of the company’s stock.

Shares of Laboratory Corp. of America Holdings (NYSE LH) traded down $0.47 during mid-day trading on Tuesday, hitting $155.79. 527,300 shares of the stock traded hands, compared to its average volume of 720,110. The company has a market cap of $15,907.27, a P/E ratio of 16.80, a price-to-earnings-growth ratio of 1.66 and a beta of 0.87. Laboratory Corp. of America Holdings has a 12-month low of $126.44 and a 12-month high of $164.22. The company has a quick ratio of 1.75, a current ratio of 1.89 and a debt-to-equity ratio of 1.18.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.08. The firm had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.55 billion. Laboratory Corp. of America had a net margin of 7.40% and a return on equity of 16.75%. The company’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the firm earned $2.25 EPS. equities analysts expect that Laboratory Corp. of America Holdings will post 9.52 earnings per share for the current year.

Several equities research analysts recently issued reports on LH shares. Robert W. Baird restated a “hold” rating and issued a $166.00 target price on shares of Laboratory Corp. of America in a report on Tuesday, October 17th. ValuEngine upgraded shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. Mizuho set a $165.00 price target on shares of Laboratory Corp. of America and gave the stock a “neutral” rating in a research report on Friday, December 1st. Wells Fargo & Company began coverage on shares of Laboratory Corp. of America in a research report on Thursday, October 12th. They issued an “outperform” rating and a $175.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating and set a $170.00 price target on the stock in a research report on Tuesday, October 10th. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $170.92.

In other news, Director Dwight Gary Gilliland sold 971 shares of the firm’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $153.52, for a total transaction of $149,067.92. Following the sale, the director now directly owns 3,501 shares in the company, valued at approximately $537,473.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.90% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Laboratory Corp. of America Holdings (LH) Stake Lowered by Asset Management One Co. Ltd.” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/laboratory-corp-of-america-holdings-lh-stake-lowered-by-asset-management-one-co-ltd/1759549.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.